Pfizer’s breast cancer drug too expensive for NHS
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
List view / Grid view
News
Immunotherapy treatment fast-tracked under UK’s access to medicines scheme
2 February 2017 | By Niamh Marriott, Digital Editor
From today, UK patients with an incurable form of bladder cancer can access the new immunotherapy, atezolizumab, following a positive Scientific Opinion...
Linkam launches the CMS196M for enhanced Cryo-correlative Microscopy with greatly improved work flow
Linkam Scientific Instruments, announce the launch of the CMS196M for enhanced Cryo Correlative Microscopy with greatly improved work flow...
7th Annual Strategic Alliance Management for Pharma
25 January 2017 | By marcus evans
This marcus evans forum will help delegates to structure the Alliance management internally as well as to offer an insight on the responsibilities and roles of the Alliance function...
Wickham Laboratories case study on the bioburden of the new £5 polymer note
25 January 2017 | By Wickham Laboratories
Wickham Laboratories Ltd is pleased to provide the results of our case study on the bioburden of the new polymer £5 note...
Customised pharmaceutical sieves for high-containment screening
Russell Compact Sieve combined with high containment isolator provide innovative screening solution for pharmaceutical manufacturer.
EMA validates Gilead’s marketing application for their Hep C therapy
23 January 2017 | By Niamh Marriott, Digital Editor
The application is supported by data from two Phase 3 studies, which evaluated 12 weeks of the fixed-dose combination in antiviral-experienced patients...
French drug developer Ethypharm acquires UK-based Martindale Pharma
Ethypharm has signed a definitive agreement to acquire Martindale Pharma.
Researchers discover severe side effects of approved multiple sclerosis medication
20 January 2017 | By Niamh Marriott, Digital Editor
The multiple sclerosis therapy alemtuzumab can trigger severe, unpredictable side effects...
Panacea initiates Phase I prostate cancer vaccine therapy trial
19 January 2017 | By Niamh Marriott, Digital Editor
Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the…
EU approval for Sanofi’s type 2 diabetes treatment
19 January 2017 | By Niamh Marriott, Digital Editor
Suliqua is an innovative new combination therapy that has the potential to address significant unmet needs for people living with type 2 diabetes in Europe
Eli Lilly to aquire pain biotech CoLucid for $960 million
19 January 2017 | By Niamh Marriott, Digital Editor
This transaction will be acting to enhance Lilly's existing portfolio in pain management for migraine, while adding a potential near-term launch...
AgileBio announces a new mobile app: LabCollector Stock Manager
19 January 2017 | By AgileBio
AgileBio announces a new app for mobile phones...
Ensuring moisture-analysis accuracy with enhanced process security
16 January 2017 | By Mettler Toledo
METTLER TOLEDO’s firmware version 2.20 for its Excellence Moisture Analyzers HX204 and HS153 allows individual methods assignment to ensure users follow SOPs and avoid mistakes. This added level of security saves time and helps to eliminate costly rework...
FDA extends review period for Eli Lilly’s rheumatoid arthritis drug
16 January 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly and Incyte’s new drug application for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA).
